Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET
Company Participants
Austin Murtagh - Director, Precision AQ
Greg Divis - Chief Executive Officer
Richard Kim - Chief Commercial Officer
Jennifer Gudeman - Senior Vice President, Medical & Clinical Affairs
Tom McHugh - Chief Financial Officer
Conference Call Participants
Andrew Tsai - Jefferies
François Brisebois - Oppenheimer
Ami Fadia - Needham & Company
David Amsellem - Piper Sandler
Marc Goodman - Leerink
Fatima Amanat - UBS
Oren Livnat - H.C. Wainwright
Myriam Belghiti - LifeSci Capital
Matt Kaplan - Ladenburg Thalmann
Brandon Folkes - Rodman & Renshaw
Operator
Greetings, and welcome to Avadel Pharmaceuticals' Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. The question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.
It is now my pleasure to introduce Austin Murtagh with Precision AQ. Thank you. You may begin.
Austin Murtagh
Good morning, and thank you for joining us on our conference call to discuss Avadel's second quarter 2024 results. As a reminder, before we begin, the following presentation includes several matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.
These risks and uncertainties are described in Avadel's public filings under the Exchange Act included in the Form 10-K for the year ended December 31, 2023, which was filed on February 29, 2024, and subsequent SEC filings. Except as required by law, Avadel undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events or otherwise.
On the call today are Greg Divis, Chief Executive Officer; Richard Kim, Chief Commercial Officer; Dr. Jennifer Gudeman, Senior Vice President of Medical and Clinical Affairs; and Tom McHugh, Chief Financial Officer.
At this time, I'll turn the call over to Greg.
Greg Divis
Thank you, Austin. Good morning, everyone, and thank you for joining us for this quarterly update. Following my opening remarks, Richard will provide an update on our launch progress, Jennifer will walk through our Phase 3 idiopathic hypersomnia or IH clinical trial, Tom will then review our second quarter financial results and we will conclude with a question-and-answer session.
The second quarter marked the one-year anniversary of introducing LUMRYZ to the market, and I'm immensely proud of the work done by our team and the impact we have made within the narcolepsy community. From the start, we recognized that oxybate-eligible patients deserve a once-at-bedtime treatment option that address their needs where first-generation oxybates fell short. Our team's relentless determination in serving people with narcolepsy has been the driving force behind our tremendous progress.